Department of Breast Surgery, West China Hospital, Sichuan University.
Department of Breast Surgery, The People's Hospital of Pengzhou, Chengdu, Sichuan Province, China.
Eur J Cancer Prev. 2022 Jan 1;31(1):54-63. doi: 10.1097/CEJ.0000000000000667.
Inflammatory bowel disease (IBD) has been found to be correlated to increased risk of both gastrointestinal and extraintestinal malignancies. It still remains conflicting whether IBD has influence on risk of breast cancer, requesting further investigations. A systematic literature research before June 2020 was conducted in PubMed and Web of Science databases. Observational studies reporting incident breast cancer after IBD diagnosis and providing measures of association were included in the meta-analysis. The pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to evaluate the associations between IBD and risk of breast cancer. Our analysis included 16 cohort studies and the overall pooled OR in patients with IBD was 0.94 (95% CI, 0.82-1.06). In further subgroup analysis, no significant association with breast cancer risk among patients with Crohn's disease (OR, 0.91; 95% CI, 0.70-1.12) and ulcerative colitis (OR, 0.99; 95% CI, 0.90-1.08). For geographic differences, the summary OR of populations in Asia (OR, 1.01; 95% CI, 0.73-1.30) was only numerically larger than that in European populations (OR, 0.90; 95% CI, 0.75-1.06). Our findings indicated that IBD had no significant influence on breast cancer risk regardless of different IBD types and geographical areas.
炎症性肠病（IBD）已被发现与胃肠道和肠外恶性肿瘤的风险增加相关。IBD 是否会影响乳腺癌的风险仍存在争议，需要进一步研究。我们在 2020 年 6 月之前在 PubMed 和 Web of Science 数据库中进行了系统的文献检索。纳入了报道 IBD 诊断后乳腺癌发病情况并提供关联度量的观察性研究进行荟萃分析。计算汇总优势比（OR）及其 95%置信区间（CI）来评估 IBD 与乳腺癌风险之间的关系。我们的分析包括 16 项队列研究，IBD 患者的总体汇总 OR 为 0.94（95%CI，0.82-1.06）。进一步的亚组分析显示，克罗恩病（OR，0.91；95%CI，0.70-1.12）和溃疡性结肠炎（OR，0.99；95%CI，0.90-1.08）患者与乳腺癌风险无显著相关性。按地理位置进行亚组分析时，亚洲人群（OR，1.01；95%CI，0.73-1.30）的汇总 OR 仅略高于欧洲人群（OR，0.90；95%CI，0.75-1.06）。我们的研究结果表明，无论 IBD 类型和地理区域如何，IBD 对乳腺癌风险均无显著影响。
